Ustekinumab Shows High Retention and Safety for IBD Patients in Real-World Study
Ustekinumab demonstrates high drug retention and a strong safety profile in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study published in Cureus. The research indicates the medication is well-tolerated and effective for long-term management of Crohn’s disease and ulcerative colitis within real-world clinical settings.
The study focused on patients in Qatar to determine how many individuals continued treatment over time and what adverse effects occurred. Drug retention—the percentage of patients who stay on a medication without switching or stopping—serves as a primary indicator of both the drug’s effectiveness and its tolerability. According to the Cureus report, Ustekinumab maintained high retention rates, suggesting it’s a viable long-term option for those who don’t respond to traditional therapies.
How effective is Ustekinumab for IBD in real-world settings?
Ustekinumab, marketed as Stelara, works by blocking two specific proteins in the body, interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in the inflammatory response. According to the U.S. Food and Drug Administration (FDA), the drug is approved for adults with moderately to severely active Crohn’s disease who have had an inadequate response to immunomodulator therapy.
The Qatari study found that a significant majority of patients remained on the drug, reflecting a positive “real-world” response. This mirrors broader trends in biologic therapy. While clinical trials often use strict inclusion criteria, real-world data includes patients with more complex medical histories. The Cureus findings suggest that the efficacy seen in controlled trials translates well to general clinical practice.
For patients with ulcerative colitis, the Mayo Clinic notes that biologics like Ustekinumab help induce and maintain remission by reducing the intestinal inflammation that causes ulcers and bleeding.
What are the safety risks associated with Ustekinumab?
The retrospective study reported a favorable safety profile with few serious adverse events. Most side effects were mild and manageable. According to the drug’s prescribing information, the most common adverse reactions include nasopharyngitis (common cold), headache, and injection site reactions.
Because Ustekinumab modulates the immune system, there’s an increased risk of infections. The National Library of Medicine archives indicate that while serious opportunistic infections are rare, clinicians typically screen patients for tuberculosis (TB) and hepatitis B before starting treatment. The Qatari cohort showed that these risks remained low, confirming the drug’s safety in a diverse patient population.
How does this study compare to global IBD data?
The findings in Qatar align with global data but highlight important differences between trial settings and daily practice. In the original UNITI clinical trials, Ustekinumab showed high efficacy in inducing remission. However, real-world studies, including the one in Cureus, often show slightly lower response rates than trials because the patient pool is less curated.
When compared to TNF inhibitors—such as infliximab or adalimumab—Ustekinumab often demonstrates better drug persistence. This means patients stay on Ustekinumab longer because it typically has fewer “secondary failures,” where the body develops antibodies against the drug, rendering it ineffective over time.
| Feature | TNF Inhibitors (e.g., Infliximab) | Ustekinumab (Stelara) |
|---|---|---|
| Target | TNF-alpha | IL-12 and IL-23 |
| Immunogenicity | Higher risk of antibody formation | Lower risk of antibody formation |
| Retention | Variable; often declines over time | Generally higher long-term retention |
Who is the ideal candidate for this biologic therapy?
Physicians typically reserve Ustekinumab for patients who’ve failed first-line treatments. According to the Crohn’s & Colitis Foundation, this often includes patients who didn’t respond to corticosteroids or those who experienced severe side effects from TNF inhibitors.
The drug’s dosing schedule—an initial intravenous infusion followed by subcutaneous injections every eight weeks—makes it more convenient than drugs requiring frequent clinic visits. This convenience likely contributes to the high retention rates noted in the Qatari study.
Frequently Asked Questions
Is Ustekinumab a cure for IBD?
No. According to medical consensus, IBD is a chronic condition. Ustekinumab manages symptoms and induces remission, but it doesn’t cure the disease.
How long does it take for Ustekinumab to work?
Response times vary. Some patients feel improvement within weeks, but the FDA guidelines and clinical data suggest that full assessment of the drug’s effectiveness usually takes several months of consistent dosing.
Can Ustekinumab be used with other medications?
Yes, some doctors prescribe it alongside immunomodulators. However, the risk of infection increases when combining biologics. Patients must be monitored closely by a gastroenterologist.
Worth a look